Report

LPCN Gets Lean Guiding Tlando Through Approval Process.

Underlying
Lipocine Inc

Lipocine is a pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men's and women's health. The company's key product candidate, TLANDO?, is an oral testosterone replacement therapy. Additional pipeline candidates include LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of non-alcoholic steatohepatitis, LPCN 1111, an oral testosterone therapy product with the potential for once daily dosing, and LPCN 1107, which has the potential to become an oral hydroxyprogesterone caproate product indicated for the prevention of recurrent preterm birth.

Provider
Zacks
Zacks

​Zacks Investment Research is a Chicago based firm with over 30 years of experience in providing institutional and individual investors with the analytical tools and financial information necessary to the success of their investment process.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch